Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA583420
Title Screening and Selection of New Antagonists of the RING-Mediated Hdm2/Hdmx Interaction.
Publication Date May 2013
Media Count 120p
Personal Author G. Wahl J. A. Camarero K. Jagadish M. Wade Y. Ji
Abstract Prostate cancer poses a major public health problem in the United States and worldwide. It has the highest incidence and is the second most common cause of cancer deaths in North American men resulting in over 30,000 deaths per annum. Consequently, there is an urgent need to develop novel therapeutic approaches. We propose to use a novel cyclotide-based molecular scaffold for generating molecular libraries that will be screened and selected in vivo to identify antagonists of the RING-mediated Hdm2/Hdmx interaction. Our innovative approach will use cell-based E. coli libraries in which individual bacteria express a different cyclotide. This comprises a new single cell-single compound approach to identify protein-protein binding antagonists. These compounds will be subjected to a two-step screen, the first involving a high throughput FRET-based FACS screen in bacteria, and the second a bioluminescence complementation assay in cancer cells. Together, these assays will identify cyclotides that disrupt Hdm2-Hdmx interactions, activate p53, and elicit p53- dependent cytotoxicity in prostate cancer cells. During the second year of this project we have accomplished the following: (1) Developed a more efficient method for the biosynthesis of cyclotides in E. coli cells; (2) We have validated our FRET-based reporter to sort cell populations; (3) Developed and characterized a novel cyclotide with p53 activating properties.
Keywords Bacteria
Escherichia coli
In vivo analysis
Pharmacological antagonists
Prostate cancer
Public health

Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
Corporate Author University of Southern California, Los Angeles.
Document Type Technical report
Title Note Final rept. 1 Mar 2010-28 Apr 2013.
NTIS Issue Number 1401
Contract Number W81XWH-10-1-0151

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader